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It has been suggested, though still unproven, that high altitude (HA) exposure is 
proarrhythmic and could potentially contribute to an increased risk of sudden cardiac 
death (SCD).1,2  However, there are very limited data, particularly above 5000m to 
substantiate this claim. We hypothesised that extreme HA leads to an increased risk of 
pathological cardiac tachyarrhythmias, detected using an implantable cardiac monitor 
(ICM).  
Sixteen healthy adult Caucasian male British Military servicemen underwent 
continuous ECG monitoring, using a Reveal LINQ ICM ( Medtronic Ltd), for >7 weeks 
before, during and >8 weeks after an attempted summit of Mount Dhaulagiri (8,167 m). 
They were required to have a normal 12-lead ECG and transthoracic echocardiogram at 
recruitment and were excluded if they had a history of cardiac arrhythmia.  They 
underwent written informed consent and the study was approved by the Ministry of 
Defence Research and Medical Ethics Committee. The participants flew from the UK to 
Kathmandu, Nepal (1400m, days 1-2), then by road (day 3-4) to 2679m. Thereafter, 
they trekked carrying moderate loads to 3720m (day 5), 4150m (day 7) and 5140m 
where they remained (days 11-24) for attempts on 6035m and 6800m peaks. One 
subject aborted at 4100m, due to severe gastrointestinal symptoms. On day 25, five 
subjects descended and 10 climbers remained at 4800m for an attempted summit of 
Mount Dhaulagiri over days 26-51(days 26-51). The subjects were monitored 
wirelessly pre and post-departure (Medtronic MyCareLinkTM Monitor) and during 
trekking using a portable Medtronic Programmer every 2-5 days, depending on 
environmental conditions.    
The subjects were 35.1±6.6 (24-48) years. Fifteen (93.8%) achieved an altitude 
of >6035m, six to 6800m, one to 7100m and three to 7500m. Unfortunately, an 
attempted summit of Mount Dhaulagiri became impossible, due to adverse weather 
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conditions.  SpO2 significantly fell at increasing HA from 96.4±1.6% at 1400m to 
93.2±2.8% at 2650m, 88.8±3.5% at 4100m, 80.6±5.0% at 5140m and 78.1±4.5% at 
5340 (Ordinary ANOVA P<0.0001).  The ICM rhythm-detection settings are shown in 
table 1 (footnote). Significant rhythm abnormalities were observed in 9 out of 16 
subjects (56.3%) at HA and only at >4100m. Symptom-related device activation was 
triggered on 18 occasions in 8/16 subjects at HA and related to extreme breathlessness 
and palpitations. Subject five developed an episode of nocturnal symptomatic rapid 
atrial fibrillation (AF) at 4100m, during the initial ascent phase, which occurred 
immediately after drinking cold water. It lasted for 282 minutes at a mean ventricular 
rate 133/minute.  Subject four, developed an episode of supraventricular tachycardia 
(SVT) lasting for 30.8 seconds (mean rate 207/ minute). It occurred immediately on 
attempting to lift a 30kg load, at 5200m and was associated with sudden and transient 
light-headedness and breathlessness.  
Significant pauses (>3 seconds) were identified at HA in 8 out of 15 (53.3%) 
subjects at HA at >4800m only, with none detected in any subjects below this altitude 
(Fisher’s Exact Test p=0.0008). There were 82 pauses (3.0-7.0s) in total, which were 
sinus in 80 with evidence of high grade heart block in two cases (mean 
number10.3±14.1; range 1-41) (table 1).  The number of pauses increased with altitude 
gain from 0 at <4800m to 4.2 at 4800m and 14.3 at >6000m (Kruskal-Wallis Test 
P<0.0001) with 19.3±20.6 pauses at 7550m (n=3) versus 1.9±4.2 among the rest of the 
subjects (n=13; Chi-squared Test p=0.007).  The number of pauses increased with 
duration of HA exposure: 6 during first 17 days (tercile, 15-16 subjects), 29 during days 
18-34 (10-15 subjects) and 47 (10 subjects) during days 35-51. The pauses typically 
occurred following cyclical periods of heart rate acceleration then deceleration 
preceding it.   
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This is the first study to convincingly demonstrate the pro-arrhythmic risks of 
significant HA and to the author’s knowledge the first to continuously monitor healthy 
subjects above 6325m at terrestrial HA. In the only previous ICM study at HA nine 
subjects were studied using first generation Reveal ICM, which lacked auto-detection 
capabilities and only two subjects were assessed at 6325m.1 They observed one short-
lived episode of atrial flutter at 150/minute (8.5 minutes) immediately after a severe 
exertion at 4500 m. The episode of nocturnal AF detected in our study would suggest 
vagally-mediated AF. We would also postulate that the pauses observed in our study 
were likely physiological and also related to the effects of increased nocturnal vagal 
tone and sleep-disordered breathing which are well recognised at HA.3,4  We believe the 
episode of SVT relates to the combination of sympathetic activation, hypoxia and 
sudden explosive exercise at HA. In addition to the factors outlined above the 
proarrhythmic effects of HA may be partly explained by other factors including 
acclimatization, changes in heart rate variability, sleep deprivation, dehydration and 
anxiety.5 
In conclusion HA exposure to >4100m is associated with significant brady and 
tachy-arrhythmias in healthy adult men supporting a potential proarrhythmic risk. There 
was no link between HA and sustained ventricular arrhythmias linked to an increased 
risk of SCD.  
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Table 1.  ICM detection settings, key cardiac rhythm findings and altitudes 
achieved  
Subject 
number  
Age  Maximal 
altitude 
achieved 
Significant 
Findings  
Key Abnormalities No of pause 
Episodes 
Longest pause 
duration in 
seconds 
1 30 6035m No None - - 
2 40 6200m No None - - 
3 41 7550m Yes Pauses 41 6.0 
4 30 6800m Yes SVT and pauses 5 5.0 
5 32 7550m Yes Atrial fibrillation - - 
6 24 4100m No None*  - - 
7 38 6200m Yes Pauses 15 4.0 
8 25 6800m No None - - 
9 48 6800m Yes Pause 1 3.3 
10 30 7550m Yes Pauses 17 7.0 
11 33 6035m Yes Pause 1 4.4 
12 41 7100m No None - - 
13 38 6800m No None - - 
14 38 6035m No None - - 
15 32 6800m Yes Pause 1 3.4 
16 41 6200m Yes Pause 1 5.0 
SVT, supraventricular tachycardia; *descended due to gastrointestinal illness; Tachycardias 
were defined as a heart rate/minute >230-age in years for >16 beats; bradycardia as a heart rate 
<30/minute for >12 beats, pause R-R interval >3 seconds and atrial 
tachycardia/fibrillation/flutter as episodes fitting morphology detection criteria lasting 
>10minutes. 
